Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2006-08-15
2006-08-15
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S141100, C424S155100, C424S134100, C424S133100
Reexamination Certificate
active
07090843
ABSTRACT:
The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
REFERENCES:
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5677430 (1997-10-01), Goodwin et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5866372 (1999-02-01), Stein et al.
patent: 6033876 (2000-03-01), Lemke et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2005/0123536 (2005-06-01), Law et al.
patent: 19543039 (1996-11-01), None
patent: 0 678 523 (1995-10-01), None
patent: WO 91/07437 (1991-05-01), None
patent: WO 96/22384 (1996-07-01), None
patent: WO 97/17374 (1997-05-01), None
patent: WO 01/80880 (2001-11-01), None
patent: WO 05/001038 (2005-01-01), None
Engert, et al., 1999, Seminars in Hematology, 36(3)282-289.
da Costa, et al., 2000, Cancer Chemother Pharmacol, 46(suppl):S33-S36.
Barth et al (Jun. 2000, Blood, vol. 95, p. 3909-14).
Weigert et al (Nature Dec. 21-28, 1978;276:785-90, abstract).
Falini et al., 1995, Blood, vol. 85, pp. 1-14.
Tian et al., Cancer Res. Nov. 15, 1995; 55(22): 5335-41.
Voet et al., (1990, Biochemistry, John Wiley & Sons, p. 1099-1101 only).
Arndt et al., 1999, “A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplantated Human Hodgkin's Tumors,” Blood 94(8):2562-2568.
Barth et al., 2000, “Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice,” Blood 95:3909-3914.
Bowen et al., 1993, “Functional Effects of CD30 on a Large Granular Lymphoma Cell Line, YT,” J. Immunol. 151:5896-5906.
Cerutti et al., 1998, “CD30 Is a CD40-Inducible Molecule that Negatively Regulates CD40-Mediated Immunoglobulin Class Switching in Non-Antigen-Selected Human B Cells,” Immunity 9:247-256.
Del Prete et al., 1995, “CD30-mediated Signaling Promotes the Development of Human T Helper Type 2-like T Cells,” J. Exp. Med. 182:1655-1661.
Dürkop et al., 1992, “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.,” Cell 68:421-427.
Engert et al., 1990, “Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease,” Cancer Res. 50:84-88.
Engert et al., 1999, “Treatment of Advanced Hodgkin's Lymphoma: Standard and Experimental Approaches,” Seminars on Hematology 36(3):282-289.
Falini et al., 1992, “In vivotargeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence,” British J. Haemat. 82:38-45.
Falini et al., 1992, “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,” The Lancet 339:1195-1196.
Franke et al., 2000, “Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies,” Hybridoma 19:43-48.
Grell et al., 1999, “Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF,” EMBO J. 18(11):3034-3043.
Gruss et al., 1994, “Pleiotrophic Effects of the CD30 Ligand on CD30-Expressing Cells and Lymphoma Cell Lines,” Blood 83(8):2045-2056.
Hansen et al., 1991, “Antibody-enhanced shedding of the CD30 (Ki-1) antigen and biochemical analysis of its soluble form,” Immunobiol. 183:214.
Hecht et al., 1985, “Production and Characterization of a Monoclonal Antibody That Binds Reed-Sternber Cells,” J. Immunol. 134(6):4231-4236.
Horn-Lohrens et al., 1995, “Shedding of the Soluble Form of CD30 From the Hodgkin-Analogose Cell Line L540 is Strongly Inhibited by a new CD30-Specific Antibody (Ki-4),” Int. J. Cancer 60:539-544.
Hsu et al., 1987, “Effect of Monoclonal Antibodies Anti-2H9, Anti-IRac, and Anti-HeFi-1 on the Surface Antigens of Reed-Sternberg Cells,” JNCI 79(5):1091-1099.
Hübinger et al., 1999, “The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the suface receptor CD30 but is not activated by CD30 stimulation,” Exp. Hematol. 27:1796-1805.
Josimovic-Alasevic et al., 1989, “Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay,” Eur. J. Immunol. 19:157-162.
Leca et al., 1994, “A Monoclonal Antibody to the Hodgkin's Disease-Associated Antigen CD30 Induces Activation and Long-Term Growth of Human Autoreactive γō T Cell Clone,” Cell. Immunol. 156:230-239.
Masuda et al., 1998, “Dual action of CD30 antigen: Anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells,” Int. J. Hematol. 67:257-265.
May et al., 1990, “Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells,” J. Immunol. 144:3637-3642.
Mir et al., 2000, “Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells,” Blood 96(13):4307-4312.
Nawrocki et al., “Biochemical and Structural Properties of a Hodgkin's Disease-Related Membrane Protein,” J. Immunol. 141:672-680.
Pallesen, 1990, “The diagnostic significance of the CD30 (Ki-1) antigen,” Histopatholgoy 16:409-413.
Powell et al., 1998, “Construction and expression of a soluble form of human CD30 ligand with functional activity,” J. Leukocyte Biology 63:752-757.
Press et al., 1988, “Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells,” J. Immunol. 141:4410-4417.
Renner et al., 2000, “Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody,” Cancer Immunol. Immunother. 49:173-180.
Schwab et al., 1982, “Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells,” Nature 299:65-67.
Schwarting et al., 1989, “BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope,” Blood, Blood 74:1678-1689.
Smith et al., 1993, “CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF,” Cell 73:1349-1360.
Tian et al., “in vivoAntitiumor Effects of Unconjugated CD30 Monoclonal Antibodies of Human Anaplastic Large-Cell Lymphoma Xenografts,” Cancer Res. 55:5335-5341.
Tsutsumi et al., 2000, “Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity,” Proc. Natl. Acad. Sci, USA 97:8548-8553.
Tutt et al., 1998, “Monoclon
Francisco Joseph A.
Risdon Grant
Siegall Clay
Wahl Alan F.
Conforti Vita G.
Jones Day
Sandbaken Mark G.
Seattle Genetics Inc.
Yu Misook
LandOfFree
Recombinant anti-CD30 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant anti-CD30 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-CD30 antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702620